Shanghai - Delayed Quote CNY
Shanghai Serum Bio-Technology Co., Ltd. (688163.SS)
17.41
+0.23
+(1.34%)
At close: 3:00:05 PM GMT+8
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Tiejiong Fan | GM & Director | -- | -- | 1985 |
| Mr. Shaoyang Li | Chief Financial Officer | -- | -- | 1971 |
| Ms. Qiong Cheng | Deputy GM & Board Secretary | -- | -- | 1976 |
| Mr. Hao Zhang | General Manager Assistant | -- | -- | 1971 |
| Mr. Liangjun Peng | Deputy General Manager | -- | -- | 1961 |
| Binsheng Chen | Accounting Supervisor | -- | -- | -- |
Shanghai Serum Bio-Technology Co., Ltd.
No. 1288, Huaqing Road
Qingpu District
Shanghai, 201707
China
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Corporate Governance
Shanghai Serum Bio-Technology Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
September 12, 2024 at 12:00 AM UTC
Ex-Dividend Date